Biopharmaceutical Manufacturing, Upstream, Downstream …
WEBThe San Diego-based biotech company Candid Therapeutics has launched with a huge $370 million with the aim to develop T-cell engager therapies for autoimmune diseases. Adaptin Bio has announced that the FDA has given the green light to start phase 1 clinical trials for its program APTN-101 targeting glioblastoma, the most common and aggressive ...
About us - biopharma-reporter.com
WEBAbout us. News and analysis on the clinical development and manufacture of large molecule drugs. , the specialist B2B media, business intelligence and events group dedicated to helping businesses succeed. Our diverse portfolio of category-leading brands serves a global audience of almost 5M monthly users, supported by …
US pharma hubs: The rising stars to watch
WEBMay 4, 2022 · US pharma hubs: The rising stars to watch. CPhI North America 2022 host city Philadelphia is set to become one of the world’s biggest cell and gene therapy manufacturing hubs. But it’s just one of many centers of innovation that are helping drive the US pharma and biopharma industry. The big four – San Diego, Philadelphia, San Francisco ...
Thermo Fisher boosts viral vector manufacturing capabilities with ...
WEBJan 15, 2021 · The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m (€725m) in cash. The acquisition will help the contract and development manufacturing ...
GlobalData identifies Top 20 global biopharmaceutical companies
WEBDec 22, 2022 · Expanding generic drug competition and a decline in the demand for COVID-19 vaccines and therapies have brought down the aggregate market capitalization of the global top 20 biopharmaceutical companies by 9.1%. The total value wsa $3.45 trillion in Q2 2022, with that dropping to $3.14 trillion in …
Gamma Biosiences takes majority stake in Mirus Bio
WEBMay 21, 2021 · Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US. Originally developed for therapeutic delivery of RNA, Mirus’ LPNCs have been adapted for a …
Building a biotech hub: Switzerland focuses on mRNA, CGT and …
WEBSep 8, 2021 · There are 314 biotech companies in Switzerland: broken down into 251 developers and 63 suppliers. Swiss life science exports were valued at CHF 99.1bn ($108bn USD) in 2020 and accounted for 44% of total exports. The sector has grown by a factor of 4.5 since 2000, when life sciences accounted for 17% of …
AbbVie’s Produodopa holds potential to become first-choice …
WEBJan 11, 2024 · AbbVie’s Produodopa is the first-to-market subcutaneous infusion of levodopa. Produodopa uses a VYAFUSER pump that maintains a continuous, steady flow of levodopa throughout the day to control motor fluctuations in the form of off-episodes, dyskinesia, and hyperkinesia. This novel delivery system of …
Xbiome acquires live biotherapeutic product program targeting ...
WEBApr 27, 2022 · The deal adds a third clinical-stage program to Xbiome’s rapidly growing pipeline. The oral live biotherapeutic product (LBP) program, M201, is designed for patients with mild to moderate ulcerative colitis. It is comprised of a of commensal bacteria that were selected based on their ability to modulate ulcerative colitis-relevant cellular ...
rBIO completes analytical characterizations of insulin drug for ...
WEBJan 29, 2024 · Synthetic biology company rBIO has completed all required analytical characterizations of its insulin biosimilar, R-biolin. R-biolin, the company’s lead biologic drug, aims to disrupt the $90 billion insulin market through a biosimilar manufacturing technique that can be ‘massively’ scaled to yield cost savings. Moving forward, rBIO says ...